Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-03-31
2008-12-23
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S281000, C514S263320, C514S252170, C514S183000, C514S081000, C514S110000, C514S234200, C514S252160, C514S151000, C514S008100, C514S009100, C514S027000, C514S167000, C514S015800, C514S221000, C514S245000, C424S649000, C424S094400
Reexamination Certificate
active
07468372
ABSTRACT:
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
REFERENCES:
patent: 5571813 (1996-11-01), Ruhter et al.
patent: 5602136 (1997-02-01), Ruhter et al.
patent: 5602137 (1997-02-01), Ruhter et al.
patent: 5688949 (1997-11-01), Inoue et al.
patent: 5707997 (1998-01-01), Shoji et al.
patent: 5919815 (1999-07-01), Bradley et al.
patent: 6040321 (2000-03-01), Kim et al.
patent: 6191131 (2001-02-01), He et al.
patent: 6262096 (2001-07-01), Kim et al.
patent: 6413974 (2002-07-01), Dumont et al.
patent: 6723136 (2004-04-01), Pruche
patent: 2002/0124330 (2002-09-01), Pruche
patent: 2002/0178512 (2002-12-01), Pastore et al.
patent: 102 23 917 (2003-12-01), None
patent: 0 714898 (1996-06-01), None
patent: 0 628 559 (2002-04-01), None
patent: 1 199 306 (2002-04-01), None
patent: 1 210 931 (2002-06-01), None
patent: 1 334 973 (2003-08-01), None
patent: 40002672 (1965-02-01), None
patent: 41014423 (1966-08-01), None
patent: 41015583 (1966-09-01), None
patent: 41016288 (1966-09-01), None
patent: WO 95/35298 (1995-12-01), None
patent: WO 01/62220 (2001-08-01), None
patent: WO 02/40485 (2002-05-01), None
patent: WO 02/50079 (2002-06-01), None
patent: WO 03/091256 (2003-11-01), None
Fischer, P.M.; Gianella-Borradori, A.; CDK inhibitors in clinical development for the treatment of cancer, Expert. Opin. Investig. Drugs; 2003; 12(6); 955-970.
Fischer, P.M.; Gianella-Borradori, A.; Recent progress in the discovery and development of cyclin-dependent kinase inhibitors, Expert. Opin. Investig. Drugs; 2005; 14(4); 457-477.
Fischer, P.M.; Gianella-Borrador A.;CDK inhibitors in clinical development for the treatment of cancer, Expert. Opin. Investig. Drugs; 2003; 12(6); 955-970.
Chemical Abstract No. 63:10201 English Translation of JP 40002672, downloaded Sep. 1, 2007.
Chemical Abstract No. 65:108095 English Translaton of JP 41014423, downloaded Sep. 1, 2007.
Chemical Abstract No. 66:10957 English Translation of JP 41015583, downloaded Sep. 1, 2007.
Chemical Abstract No. 66:10952 English Translation of JP 41016288, downloaded Sept. 1, 2007.
Chemical Abstract No. 105:226617 English Translation of JP 61057587, downloaded Sep. 1, 2007.
Robins et al., “Purine Analog Inhibitors of Xanthine Oxidase—Structure Activity Relationships and Proposed Binding of the Molybdenum Cofactor”,J. Heterocyclic Chem., 22:601-634 (1985).
Vesely et al., “Inhibition of Cyclin-Dependent Kinases by Purine Analogues”, Eur. J. Biochem, 224: 771-786 (1994).
Kim et al., “Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities”,Journal of Medical Chemistry, Page EST:22.3, A-W. 2002.
Mettey et al., “Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects”,J. Med. Chem., 46(2): 222-236 (2003).
Novinson et al., “Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-α]pyrimidines”, J.Med. Chem., 20(2): 296-299 (1977).
Senderowicz et al., “Phase I Trial of Continous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasmns”,Journal of Clinical Oncology, 16(9): 2986-2999 (Sep. 1998).
Senderowicz et al., “Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators”,J. Natl. Cancer Inst., 92(5): 376-387 (Mar. 1, 2000).
Meijer et al., “Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5”,Eur. J. Biochem, 243:527-536 (1997).
Bible et al., “Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration”,Cancer Research, 57:3375-3380 (Aug. 15, 1997).
Shiota et al., “Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo [1,5-α]pyrimidine Derivatives”,Chem. Pharm. Bull., 47(7): 928-938 (1999).
Makisumi, Yasuo “Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-α]pyrimidines”,Chem. Pharm. Bull(1962), 10: 620-626.
West, Anthony R., “Solid State Chemistry and its Applications”,Wiley, New York, 358 and 365 (1988).
Fischer, Peter M. et al., “Recent progress in the discovery and development of cyclin-dependent kinase inhibitors”,Expert Opinion on Investigational Drugs, 14(4): 457-477 (Apr. 2005).
Fischer, Peter M. et al., “CDK inhibitors in clinical development for the treatment of cancer”,Expert Opinion on Investigational Drugs, 12(6): 955-970 (Jun. 2003).
Honma, Teruki et al., “Structure-Based Generation of a NewClass of Potent Cdk4 Inhibitors: Newde NovoDesign Strategy and Library Design”,J. Med. Chem., 44: 4615-4627 (2001).
Translation of WO 03/91256, “A Rising Sun Communications Ltd. Translation Product”, (1-62) 2003.
PCT International Search Report dated Dec. 22, 2003 for corresponding PCT Application No. PCT/US03/27564. mailing date Dec. 29, 2003.
Dillard Lawrence W.
Doll Ronald J.
Dwyer Michael P.
Girijavallabhan Viyyoor M.
Guzi Timothy J.
Farquharson-Torres Serena
Kalyanaraman Palaiyur S.
Moore Susanna
Schering Corporation
Wilson James O.
LandOfFree
Trisubstituted 4-aminopyrazolopyrimidines as cyclin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Trisubstituted 4-aminopyrazolopyrimidines as cyclin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Trisubstituted 4-aminopyrazolopyrimidines as cyclin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4039005